

**DOCKET NO.: ALLE0049-100 (17455 CIP1)**  
**U.S. Serial No. 10/666,408**

**PATENT**

### **Listing of Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-9. (canceled)

10. (currently amended) A method for treating fibromyalgia, the method comprising the step of subcutaneously or intramuscularly administering a therapeutically effective amount of a botulinum toxin to treat a patient with fibromyalgia, the botulinum toxin administering being carried out at a first location which first location is anatomically distinct from and/or anatomically distant from a second location, at which second location the patient has a fibromyalgia pain which is alleviated by the administration of the botulinum toxin at the first location, thereby treating fibromyalgia.

11. (original) The method of claim 10, wherein the first location is a peripheral location.

12. (original) The method of claim 10, wherein the second location is a locus of pain.

13. (canceled)

14. (original) The method of claim 10, wherein the first location is the head or neck of the patient.

15. (new) The method of claim 10, wherein the botulinum toxin is a botulinum toxin type A, B, C, D, E, F or G.

16. (new) The method of claim 10, wherein the botulinum toxin is a botulinum toxin type A.

**DOCKET NO.: ALLE0049-100 (17455 CIP1)**  
**U.S. Serial No. 10/666,408**

**PATENT**

17. (new) A method for treating fibromyalgia, the method comprising the step of subcutaneously or intramuscularly administering about 15-180 units of a botulinum toxin to treat a patient with fibromyalgia, the botulinum toxin administering being carried out at a first location which first location is anatomically distinct from and/or anatomically distant from a second location, at which second location the patient has a fibromyalgia pain which is alleviated by the administration of the botulinum toxin at the first location, thereby treating fibromyalgia.

18. (new) The method of claim 17, wherein the botulinum toxin is a botulinum toxin type A, B, C, D, E, F or G.

19. (new) The method of claim 17, wherein the botulinum toxin is a botulinum toxin type A.

20. (new) A method for treating fibromyalgia, the method comprising the step of subcutaneously or intramuscularly administering a therapeutically effective amount of a botulinum toxin to treat a patient with fibromyalgia, the botulinum toxin administering being carried out at a first location which first location is anatomically distinct from and/or anatomically distant from a second location, at which second location the patient has a tender point which is alleviated by the administration of the botulinum toxin at the first location, thereby treating fibromyalgia.